Menu
Recruiting NCT04159142

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Phase II Interventional Triple Negative Breast Cancer Nab-paclitaxel

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine.
Who it may be relevant to
Registry conditions: Triple Negative Breast Cancer, Nab-paclitaxel. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Overview

This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease. The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.

Interventions

  • Drug Nab-paclitaxel + Carboplatin
    nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
  • Drug Nab-paclitaxel + Capecitabine
    Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；

Primary outcome measures

  • Progression free survival (PFS) [Time frame: 3 years]
Secondary outcome measures (4)
  • PFS rate for 6 cycles [Time frame: At the end of Cycle 6 (each cycle is 21 days)]
  • Objective response rate (ORR) [Time frame: 3 years]
  • Overall survival (OS) [Time frame: 3 years]
  • Adverse events (AE) [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • Females with age between 18 to 70 years old;
  • Histologically confirmed triple negative breast cancer;
  • No more than one-line prior treatment for locally advanced or metastatic breast cancer;
  • Have at least one measurable lesion as per the RECIST criteria (version 1.1);
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one;
  • Patients with life expectancy of at least 3 months;
  • Bone marrow function：neutrophils (≥1.5×10\^9/L), platelets (≥100×10\^9/L), hemoglobin (≥90 g/L);
  • Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's syndrome ≤ 2.5 × ULN;
  • Patients had good compliance with the planned treatment, understood the research process and written informed consent.

Exclusion criteria

  • Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores;
  • Brain metastasis;
  • Recurrence or metastasis within 6 months after capecitabine withdrawal;
  • Recurrence or metastasis within 6 months after platinum withdrawal;
  • Progression in the treatment, recurrence or metastasis of paclitaxel (including albumin paclitaxel) within 6 months;
  • Patients required clinical intervention with gastrointestinal bleeding, gastrointestinal obstruction and non-feeding;
  • Patients who had Grade 2 or above Peripheral neuropathy;
  • Patients with severe systemic infection or other serious diseases;
  • Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;
  • Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;
  • Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial;
  • Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given;
  • The researchers considered the patients who were not suitable for enrollment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The Fourth Hospital of Hebei Medical University — Shijiazhuang

Identifiers

NCT: NCT04159142 · CSPC-KAL-BC-16

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗